Hexarelin

Hexarelin Peptide Detailed Overview

Hexarelin is a highly significant compound within the Growth Hormone axis research bracket, designed to stimulate and analyze the intricate cascades of systemic metabolic regeneration and endocrine pulsing.

Pharmacological Profile

Parameter	Value
Molecular Formula	C47H58N12O6
Molecular Weight	887.0 g/mol
Assay Purity	>98.0%
Appearance	Lyophilized white powder

Figure 1: Conceptual Binding Mechanism of Hexarelin

Molecular Methodology

The sequential action framework observed in experimental diagnostics:

1. The strongest potent hexapeptide GH secretagogue available.
2. Overrides standard somatostatin loops to force massive pulse clearance.
3. Significantly elevates both prolactin and cortisol.
4. Interacts directly with cardiac receptors (CD36) independent of the GH axis.
5. Can cause rapid receptor desensitization if used continuously.

Figure 2: Empirical Systemic Response Profile

Identified Research Parameters

• Vector Observation: Demonstrated explicitly profound cardioprotective and remodeling effects.
• Trial Output: Generates the highest raw peak GH pulse compared to any alternative.
• Diagnostic Core: Recommended for cyclical use to prevent terminal receptor down-regulation.

Cardioprotective Growth Hormone Secretagogue

Hexarelin (His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a hexapeptide GH secretagogue that occupies a unique position in the GHRP class due to its potent cardioprotective properties independent of GH release. While Hexarelin activates the GHS-R1a receptor on somatotrophs like other GHRPs, it additionally binds the CD36 scavenger receptor on cardiomyocytes with high affinity. CD36 activation triggers cardioprotective signaling cascades involving PPARγ, Akt, and eNOS that reduce ischemic damage, cardiac fibrosis, and atherosclerotic plaque formation.

1. GHS-R1a activation produces potent GH release, with Hexarelin generating GH pulses comparable to or exceeding GHRP-2 in amplitude.
2. CD36 receptor binding on cardiomyocytes activates PPARγ, reducing cardiac inflammatory gene expression and fibroblast collagen deposition.
3. Akt/eNOS signaling is upregulated in cardiac tissue, increasing nitric oxide production and cardioprotective vasodilation.
4. In ischemia-reperfusion models, Hexarelin pre-treatment reduces infarct size by 40–60% through mitochondrial permeability transition pore (mPTP) inhibition.
5. Hexarelin also stimulates cortisol and prolactin release (similar to GHRP-6) and produces moderate appetite stimulation through hypothalamic GHS-R1a activation.

Cardiac & Metabolic Research

• Cardiac Studies: In GH-deficient patients, Hexarelin improved left ventricular ejection fraction (LVEF) and reduced cardiac fibrosis markers independently of changes in GH/IGF-1 levels, confirming direct cardiac benefit.
• Atherosclerosis: CD36-mediated macrophage cholesterol efflux is enhanced by Hexarelin, reducing foam cell formation and atherosclerotic plaque burden in ApoE-knockout mouse models.
• Desensitization: Unlike Ipamorelin, Hexarelin shows significant GHS-R1a desensitization with chronic use, with GH response declining 50–70% over 16 weeks of daily administration.
• Cardiac Independence: Cardioprotective effects persist even after GH response desensitization, as the CD36-mediated mechanism is independent of GHS-R1a.
• Dosing: GH research: 100 μg SC, 2–3 times daily. Cardiac research protocols use varying doses. Administer on empty stomach for maximum GH response.